Randomised double-blind trial of recombinant interferon-beta for condyloma acuminatum.

  title={Randomised double-blind trial of recombinant interferon-beta for condyloma acuminatum.},
  author={Joseph Monsonego and G Cessot and Susan Ince and Andrew R. Galazka and A. K. Abdul-Ahad},
  journal={Genitourinary medicine},
  volume={72 2},
OBJECTIVE To evaluate the safety and efficacy of two intralesional doses of recombinant human interferon-beta (r-hIFN-beta: Rebif, Ares Serono), given 3 times a week for 3 weeks, in the treatment of condyloma acuminatum. DESIGN A randomised, double-blind, within-patient, placebo-controlled study. SUBJECTS 25 patients (24 males, 1 female) with a history of condyloma acuminatum. Twenty had failed previous treatment for condyloma acuminatum. In each patient, 3 distinct lesions were selected… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.


Publications referenced by this paper.
Showing 1-10 of 23 references

Prevalence of human papillomavirus in cervical cancer : a worldwide perspective

FX Bosch, MM Mafnos, N Munoz
JNat Canc Inst • 1995

Intra - lesional interferon alpha - 2 b for the treatment of genital warts

E WelanderCharles, HD Homesley, KA Smiles
AmJ Gynecol • 1990

Interferon in genital warts : much potential , modest progress

P Kirby
JAMA • 1988

Similar Papers

Loading similar papers…